Lead poisoning may be among the most pressing public health challenges faced by low and middle-income countries (LMICs) and is certainly one of the least recognized and most neglected. Lead exposure is estimated by the Institute of Health and Metrics to be responsible for 900,000 deaths per year (mo...

Drug-resistant infections kill an estimated 23,210 Japanese citizens every year. The government of Japan is considering a program that would provide minimum guaranteed revenue to the successful developers of new antibiotics. We present the results of a modelling exercise to estimate the likely retur...

Drug-resistant infections kill an estimated 7,600 UK citizens every year. Without investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from an expanded prog...

Drug-resistant infections kill an estimated 33,000 EU citizens every year. Without sufficient investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from ince...

Drug-resistant infections kill an estimated 5,400 Canadian citizens every year. Without sufficient R&D investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI ...

The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...

Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...